Upgrade to SI Premium - Free Trial

Rocket Pharmaceuticals (RCKT) Reiterated at Overweight by Cantor Fitzgerald After Update on RP-A501

October 7, 2026 6:59 AM
Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and $15.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments